ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07270666
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ctDNA Testing — GENETIC
    Patients will undergo ctDNA sampling at the 1-year timepoint using the commercially available Natera SignateraTM test.
  • Blood draw — OTHER
    at the 1-year timepoint

Study Details

The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of people in this study (for example, whether they are cancer free at the end of their participation in the study).

Key Dates

Start date
Nov 25, 2025
Status verified
Dec 2025
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ctDNA-negative group
    Participants in this group will have negative ctDNA test results at 1 year after they start standard treatment. (Negative results indicate that no cancer DNA is detected in their blood.) Participants in this group will decide with their doctor if they want to stop standard maintenance ICI treatment.
  • Experimental: ctDNA-positive group
    Participants in this group will have positive ctDNA test results at 1 year after they start standard treatment. (Positive results indicate that cancer DNA is detected in their blood.) Participants in this group will continue receiving standard treatment with their doctor.

Primary Outcome Measure

will test the feasibility of ct-DNA [ Time Frame: 1 year ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (All Protocol Activites)Basking RidgeNew Jersey07920
Ying Liu, MD
646-888-4946
Memorial Sloan Kettering Monmouth (All Protocol Activities)MiddletownNew Jersey07748
Ying Liu, MD
646-888-4946
Memorial Sloan Kettering Bergen (All Protocol Activities)MontvaleNew Jersey07645
Ying Liu, MD
646-888-4946
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)CommackNew York11725
Ying Liu, MD
646-888-4946
Memorial Sloan Kettering Westchester (All Protocol Activities)HarrisonNew York10604
Ying Lui, MD
646-888-4946
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Ying Liu, MD, MPH.
646-888-4946
Roisin O'Cearbhaill, MD
646-888-4227
Memorial Sloan Kettering Nassau (All Protocol Activities)Rockville CentreNew York11570
Ying Liu, MD
646-888-4946

Find similar trials in Basking Ridge, NJ

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Memorial Sloan Kettering Basking Ridge (All Protocol Activites)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (All Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (All Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk - Commack (All Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (All Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NY

Related Studies